Caplin Point Laboratories Limited
NSE: CAPLIPOINTMarket Closed • NSE
Day range
52 week range
Caplin Point Laboratories Limited closed at INR2301.30 (-0.02%) on volume 0.33x its 20-day average, trading 23.03% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +4% QoQ
2026-09-18
DIVIDEND Announced
Dividend - Rs 4 Per Share
2026-05-29
DIVIDEND Announced
Interim Dividend - Rs 4 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.13x
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 18 Sept 2026 | Dividend | ₹4.00 / share | — | 18 Sept 2026 |
| 30 May 2026 | Dividend | ₹4.00 / share | — | 29 May 2026 |
| 12 Sept 2025 | Dividend | ₹3.00 / share | — | 12 Sept 2025 |
| 30 May 2025 | Dividend | ₹3.00 / share | — | 30 May 2025 |
| — | Annual General Meeting | Annual General Meeting | — | 23 Sept 2024 |
| 23 Sept 2024 | Dividend | ₹2.50 / share | — | 23 Sept 2024 |
| 31 May 2024 | Dividend | ₹2.50 / share | — | 31 May 2024 |
| — | Dividend | ₹2.50 / share | — | 14 Sept 2023 |
| 09 Jun 2023 | Dividend | ₹2.00 / share | — | 09 Jun 2023 |
| — | Dividend | ₹2.00 / share | — | 21 Sept 2022 |
| 24 May 2022 | Dividend | ₹2.00 / share | — | 23 May 2022 |
| — | Dividend | ₹1.50 / share | — | 20 Sept 2021 |
| 19 May 2021 | Dividend | ₹1.50 / share | — | 18 May 2021 |
| — | Dividend | ₹0.40 / share | — | 21 Sept 2020 |
| 13 Mar 2020 | Dividend | ₹2.10 / share | — | 12 Mar 2020 |
| — | Dividend | ₹2.20 / share | — | 04 Sept 2019 |
| — | Dividend | ₹2.00 / share | — | 18 Sept 2018 |
| — | Dividend | ₹1.50 / share | — | 07 Sept 2017 |
| 20 Oct 2016 | Fv Splt Frm Rs 10 To Rs 2 | Fv Splt Frm Rs 10 To Rs 2 | — | 19 Oct 2016 |
| — | Dividend | ₹3.50 / share | — | 01 Sept 2016 |
| 16 Feb 2016 | Dividend | ₹2.50 / share | — | 15 Feb 2016 |
| — | Dividend | ₹5.00 / share | — | 29 Oct 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
IndiaHealthcare
Is Caplin Point Laboratories Limited Shariah compliant?
Caplin Point Laboratories Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.03%) complies with AAOIFI threshold (≤ 33%).
What is Caplin Point Laboratories Limited's current valuation relative to peers?
Caplin Point Laboratories Limited trades at a P/E of 26.4x compared to the sector median of 37x, and a Price-to-Book of 5.0x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.13x. Interest coverage is 790.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 5.4% while net profit growth averaged 7%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.